glp-1 obesity market news today Beyond GLP-1Rs: emerging targets poised to gain share of New weight-loss drugs surge in

,

We invite you to reach out, learn more, and discover how our specialized treatments can be a part of your recovery journey

By inhibiting the NNMT enzyme, 5-Amino-1MQ promotes the bodys ability to burn fat more efficiently, which could lead to improved cellular health and a more youthful metabolic profile

"India and China alone represent about a quarter of the worlds adult obese population, and the availability of generic semaglutide will be a big shift in how these countries manage these populations." The market is ripe in countries where semaglutide goes off patent next year, as close to one-third of the worlds adults with obesity live in those countries, says Aurelio Arias, director of thought leadership at Iqvia, a health-information company